Different combinations and elevated levels of antiviral immune signaling proteins, called interferons (IFNs), were associated with differences in the symptoms and severity of systemic lupus erythematosus (SLE), a study shows. While IFNs are known to play a role in the disease, increases in IFN levels don ‘t explain many…
A 27-year-old woman with hard-to-treat systemic lupus erythematosus (SLE), the most common type of lupus, became the first patient treated in an early clinical trial evaluating FT819, Fate Therapeutics’ off-the-shelf CAR T-cell therapy candidate. The Phase 1 study (NCT06308978), taking place at the University of Minnesota Medical…
Inflammatory macrophages, a type of immune cell tasked with clearing the body of harmful invaders and dead cells, may be linked to more severe lupus nephritis in children with systemic lupus erythematosus, a small study suggests. Those immune cells, called M1-like macrophages, appear to play a more important role…
About 91% of lupus patients report they are currently taking or had been using oral steroids to manage their symptoms, according to a global survey of more than 7,700 patients. The World Lupus Federation (WLF) released findings from the survey ahead of World Lupus Day, observed…
The U.S. Food and Drug Administration (FDA) has updated the prescribing label for Lupkynis (voclosporin), which is approved to treat a severe manifestation of lupus called lupus nephritis, to include data that shows it continues to safely preserve kidney function for up to three years. The data came…
Note: This story was updated May 6, 2024, to correct that Cullinan Therapeutics continues to pursue its oncology platform while also expanding into treatments for autoimmune diseases including lupus. Cullinan Therapeutics has announced its plans to exclusively pursue the development of its T-cell-engager CLN-978 as a treatment for…
For this Lupus Awareness Month, marked each May, the focus is on educating people about the autoimmune disorder thought to affect about 1.5 million U.S. residents and more than 5 million individuals globally. World Lupus Day, bringing disease warriors worldwide together, will be observed on May…
The first patient has been dosed in the U.S. as part of a clinical trial testing AlloNK, an experimental natural killer (NK) cell therapy candidate, in patients with lupus nephritis, one of the most common and severe complications of lupus. The open-label Phase 1 trial (NCT06265220) is…
The U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) is joining the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) to focus on CAR T-cell treatments and other engineered cell therapies, a promising new therapeutic field now being explored for lupus. “We are delighted to have…
Depression is highly prevalent among people with systemic lupus erythematosus (SLE), but often goes undiagnosed, according to a single center study in Pakistan. The “treatment of depression is a vital component in the management of these patients and should be offered where appropriate,” the researchers wrote in “…